Meeting
2022 ASCO Annual Meeting
First-line PD-1 inhibitors immunotherapy and chemotherapy combined with or without radiotherapy for patients with advanced non-small cell lung cancer.
Authors
Peng Ding
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Peng Ding , Yu Huang , Fan Tong , Lingjuan Chen , Lu Wen , Ruiguang Zhang , Shishi Cheng , Xiaorong Dong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2606)
DOI
10.1200/JCO.2022.40.16_suppl.2606
Abstract #
2606
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
Poster
2023 ASCO Annual Meeting
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
First Author: Li Zhang
Poster
2021 ASCO Annual Meeting
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
First Author: Fang Wu
Poster
2020 ASCO Virtual Scientific Program
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.
First Author: John D. Powderly II